CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2003-05-02): Fatty liver linked to high plasminogen inhibitor levels in HIV-related lipodystrophy


Fatty liver linked to high plasminogen inhibitor levels in HIV-related lipodystrophy

Last Updated: 2003-05-02 15:08:53 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Liver fat content appears to contribute to the elevated levels of plasminogen activator inhibitor-1 (PAI-1) seen in patients treated with highly active antiretroviral therapy (HAART), according to a report in the April issue of Arteriosclerosis, Thrombosis and Vascular Biology.

Dr. Jussi Sutinen, of Helsinki University Central Hospital, Finland, assessed 30 patients on HAART who had lipodystrophy (HAART+LD+) and 13 HAART-treated patients without lipodystrophy (HAART+LD-), as well as 15 HIV-negative control subjects.

Liver fart content was significantly higher in the HAART+LD+ group, at 7.6% compared with 2.1% in the HAART+LD- group and 3.6% in the HIV-negative group. Plasma levels of plasma tissue plasminogen activator (tPA), insulin and triglycerides were also higher in patients with lipodystrophy.

In addition, PAI-1 levels correlated with liver fat content but not with subcutaneous or intra-abdominal fat in the HAART+LD+ group.

The authors treated the HAART+LD+ patients for 24 weeks with rosiglitazone 8 mg daily or placebo. Rosiglitazone treatment, but not placebo, was associated with decreased plasma PAI-1, serum insulin and liver fat content (p < 0.05), and increased serum triglycerides. The agent had no effect on subcutaneous or intra-abdominal fat depots.

The authors theorize that "plasma PAI-1 concentration is likely to be regulated directly (through changes in production or uptake of PAI-1 by the liver) or indirectly (through alterations in serum insulin concentrations due to changes in hepatic insulin sensitivity) by the liver."

Arterioscler Thromb Vasc Biol 2003;23:688-694.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2017 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.